Dejan Juric

Career Trajectory

Research Cluster Map

Direct collaborators. Node size = influence, colour = community, dashed = past collaboration.

• Screen failures among patients who consented for early phase cancer clinical trials (EPCTs).

  Journal of Clinical Oncology · 2026-05-28

• Data from Acquired On-Target Alterations Drive Clinical Resistance to p53-Y220C Reactivators

  2026-04-01

• Genomic determinants of response to alpelisib plus fulvestrant in the SOLAR-1 trial

  Annals of Oncology · 2026-04-01

• Supplementary Figures S1-S6 from Acquired On-Target Alterations Drive Clinical Resistance to p53-Y220C Reactivators

  2026-04-01

• Supplementary Figure S13 from PI3Kα Inhibitor and Degrader Inavolisib Can Co-opt FGFR2 to Enhance Responses in Patients with <i>PIK3CA</i>-Mutated Solid Tumors and in Preclinical Models

  2026-01-06

• Supplementary Table S5 from PI3Kα Inhibitor and Degrader Inavolisib Can Co-opt FGFR2 to Enhance Responses in Patients with <i>PIK3CA</i>-Mutated Solid Tumors and in Preclinical Models

  2026-01-06

• Supplementary Table S4 from PI3Kα Inhibitor and Degrader Inavolisib Can Co-opt FGFR2 to Enhance Responses in Patients with <i>PIK3CA</i>-Mutated Solid Tumors and in Preclinical Models

  2026-01-06

• Supplementary Figure S1 from PI3Kα Inhibitor and Degrader Inavolisib Can Co-opt FGFR2 to Enhance Responses in Patients with <i>PIK3CA</i>-Mutated Solid Tumors and in Preclinical Models

  2026-01-06

• Supplementary Figure S11 from PI3Kα Inhibitor and Degrader Inavolisib Can Co-opt FGFR2 to Enhance Responses in Patients with <i>PIK3CA</i>-Mutated Solid Tumors and in Preclinical Models

  2026-01-06

• Supplementary Figure S7 from PI3Kα Inhibitor and Degrader Inavolisib Can Co-opt FGFR2 to Enhance Responses in Patients with <i>PIK3CA</i>-Mutated Solid Tumors and in Preclinical Models

  2026-01-06

• Supplementary Figure S6 from PI3Kα Inhibitor and Degrader Inavolisib Can Co-opt FGFR2 to Enhance Responses in Patients with <i>PIK3CA</i>-Mutated Solid Tumors and in Preclinical Models

  2026-01-06

• Supplementary Figure S10 from PI3Kα Inhibitor and Degrader Inavolisib Can Co-opt FGFR2 to Enhance Responses in Patients with <i>PIK3CA</i>-Mutated Solid Tumors and in Preclinical Models

  2026-01-06

• Supplementary Figure S9 from PI3Kα Inhibitor and Degrader Inavolisib Can Co-opt FGFR2 to Enhance Responses in Patients with <i>PIK3CA</i>-Mutated Solid Tumors and in Preclinical Models

  2026-01-06

• Supplementary Figure S12 from PI3Kα Inhibitor and Degrader Inavolisib Can Co-opt FGFR2 to Enhance Responses in Patients with <i>PIK3CA</i>-Mutated Solid Tumors and in Preclinical Models

  2026-01-06

• Figure 3 from A First-In-Human Study of the SUMOylation Inhibitor Subasumstat in Patients with Advanced/Metastatic Solid Tumors or Relapsed/Refractory Hematologic Malignancies

  2025-11-19

• Supplementary Figure 3 from A First-In-Human Study of the SUMOylation Inhibitor Subasumstat in Patients with Advanced/Metastatic Solid Tumors or Relapsed/Refractory Hematologic Malignancies

  2025-11-19

• Supplementary Figure 4 from A First-In-Human Study of the SUMOylation Inhibitor Subasumstat in Patients with Advanced/Metastatic Solid Tumors or Relapsed/Refractory Hematologic Malignancies

  2025-11-19

• Supplementary Figure 7 from A First-In-Human Study of the SUMOylation Inhibitor Subasumstat in Patients with Advanced/Metastatic Solid Tumors or Relapsed/Refractory Hematologic Malignancies

  2025-11-19

• Supplementary Figure 8 from A First-In-Human Study of the SUMOylation Inhibitor Subasumstat in Patients with Advanced/Metastatic Solid Tumors or Relapsed/Refractory Hematologic Malignancies

  2025-11-19

• Data from A First-In-Human Study of the SUMOylation Inhibitor Subasumstat in Patients with Advanced/Metastatic Solid Tumors or Relapsed/Refractory Hematologic Malignancies

  2025-11-19 · 1 citations